Uniphos Enterprises Limited (UNIENTER) AI Stock Analysis

• Market Cap: ₹7.99B
• Dividend Yield: 0.34%
• Average Volume (3M): 1.50K
• Price to Earnings (P/E): 42.1
• Beta (1Y): 1.14
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 2,022
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): 3.33
• Shares Outstanding: 69,545,845
• 10 Day Avg. Volume: 885
• 30 Day Avg. Volume: 1,505
• PEG Ratio: -38.21
• Price to Book (P/B): 0.39
• Price to Sales (P/S): 9.47
• P/FCF Ratio: -388.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ₹114.00 ▼(-21.57% Downside)

The score is held back primarily by weak operating profitability and persistently negative operating/free cash flow, despite strong revenue growth. A debt-free, equity-heavy balance sheet provides stability, but valuation is expensive (high P/E and low dividend yield) and technical signals are neutral-to-mixed with the price below key longer-term moving averages.

Positive Factors

Debt-free Balance Sheet

A zero-debt, equity-heavy balance sheet materially reduces financial distress risk and provides long-term strategic optionality. It supports funding for capex, R&D, or M&A without leverage, and cushions the business against cyclical shocks while management fixes operating performance.

Recent Revenue Growth

Sustained top-line expansion of ~25% indicates market traction and addressable demand in the company’s segments. Over 2–6 months, consistent revenue growth can enable better absorption of fixed costs and provide the pathway to margin recovery if cost structure and pricing are managed.

Specialty Chemicals Exposure

Operating in specialty chemicals and fumigation offers structural advantages: higher technical barriers, recurring B2B demand, and potential for long-term customer relationships. These attributes can support steadier revenues and differentiated pricing versus commodity chemical peers.

Negative Factors

Very Weak Core Profitability

Gross margins near zero leave almost no buffer to cover SG&A and other operating costs, making profits highly sensitive to small revenue or cost swings. Persistent negative EBIT signals core business economics need structural change to deliver sustainable earnings.

Recurring Negative Cash Generation

Repeated negative operating and free cash flow indicate the business is not self-financing, forcing reliance on equity or other sources for working capital and growth. Over months this constrains reinvestment, raises execution risk, and limits flexibility to improve operations.

Low Returns & Profit Quality

A ROE near zero on a large capital base demonstrates the company is not generating adequate returns for shareholders. Thin net margins and inconsistent profit drivers suggest earnings quality issues, making long-term value creation uncertain without structural operational improvement.

Uniphos Enterprises Limited Business Overview & Revenue Model

Company Description

Uniphos Enterprises Limited engages in trading of chemicals and other products in India. The company also invests in quoted and unquoted securities. Uniphos Enterprises Limited was incorporated in 1969 and is based in Mumbai, India. Uniphos Enterprises Limited is a subsidiary of Nerka Chemicals Private Limited.

How the Company Makes Money

Uniphos Enterprises Limited Financial Statement Overview

Summary

Balance sheet strength (zero debt, large equity base) lowers financial risk, but operating fundamentals are weak: near-zero gross margin (~0.7%), negative EBIT, very thin net margin (~0.25%), and recurring negative operating/free cash flow. Recent revenue growth (+24.9%) is a positive offset but not yet translating into durable profitability or cash generation.

Income Statement

Revenue growth is strong in the most recent annual period (+24.9%), but profitability quality looks weak: gross margin is near zero (~0.7%) and operating profit is negative (EBIT -45.7m) despite positive EBITDA, pointing to costs below the operating line weighing on results. Net income is positive (2.8m) but at a very thin net margin (~0.25%), and prior years show unusually high net margins alongside negative operating earnings, suggesting earnings are not being driven by core operations consistently.

Balance Sheet

The balance sheet is conservatively positioned with zero debt and a large equity base (equity ~27.4bn vs. assets ~28.4bn), which lowers financial risk and provides flexibility. The key weakness is low return on equity in the latest year (~0.01%), implying the capital base is not currently generating strong shareholder returns.

Cash Flow

Cash generation is a clear pressure point: operating cash flow and free cash flow are negative in the latest year (-27.2m) and also negative in the prior year (-34.7m), indicating the business is not currently funding itself through operations. While there was a positive operating cash flow year in 2022 (5.2m), the overall pattern is volatile and tilted negative, which raises execution and sustainability risk if it persists.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.14B	1.12B	506.48M	14.72M	12.22M	8.33M
Gross Profit	8.30M	8.02M	652.00K	164.00K	-11.00K	75.00K
EBITDA	16.92M	22.99M	-30.90M	-28.63M	-31.26M	-30.64M
Net Income	-3.11M	2.78M	386.14M	392.25M	546.04M	244.51M
Balance Sheet
Total Assets	0.00	28.42B	20.78B	30.95B	33.02B	27.72B
Cash, Cash Equivalents and Short-Term Investments	161.75M	162.37M	469.95M	517.30M	391.46M	451.52M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	-27.42B	1.00B	20.50M	978.68M	1.21B	569.04M
Stockholders Equity	27.42B	27.42B	20.75B	29.98B	31.81B	27.15B
Cash Flow
Free Cash Flow	0.00	-27.17M	-34.67M	-14.66M	5.20M	-45.87M
Operating Cash Flow	0.00	-27.17M	-34.67M	-14.66M	5.20M	-45.87M
Investing Cash Flow	0.00	527.70M	501.62M	406.29M	204.34M	-338.62M
Financing Cash Flow	0.00	-409.58M	-452.05M	-392.93M	-236.46M	0.00

Uniphos Enterprises Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHREEPUSHK	68 Neutral	₹10.61B	14.81	―	0.52%	28.67%	50.12%
INDOAMIN	63 Neutral	₹8.19B	11.63	―	0.38%	13.01%	32.44%
SRHHYPOLTD	63 Neutral	₹7.66B	8.58	―	0.56%	-7.93%	11.44%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
KOTHARIPET	60 Neutral	₹6.98B	10.56	―	0.81%	-4.92%	1.29%
CHEMFAB	52 Neutral	₹5.87B	-44.71	―	0.28%	5.19%	-152.09%
UNIENTER	49 Neutral	₹7.99B	42.10	―	0.34%	―	―

Uniphos Enterprises Limited Corporate Events

Uniphos Enterprises Closes Trading Window Ahead of Unaudited Results

Uniphos Enterprises Limited has announced that its trading window for company insiders will be closed from 1 January 2026 in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code on handling unpublished price-sensitive information. The restriction will remain in place until 48 hours after the company uploads its unaudited financial results for the quarter and nine months ended 31 December 2025 on the stock exchanges, a standard compliance measure aimed at preventing insider trading and ensuring fair disclosure to all market participants.